| Accession |
PRJCA013651 |
| Title |
mRNA expression profiles of BT474 cells after the treatment of pyrotinib, tamoxifen, dalpiciclib and their combination |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
|
| Organisms |
Homo sapiens
|
| Description |
The HER2+HR+ BT474 cells were treated with DMSO(control group), pyrotinib, tamoxifen, dalpiciclib, pyrotinib+tamoxifen, pyrotinib+dalpiciclib, tamoxifen+dalpiciclib and pyrotinib+tamoxifen+dalpiciclib. The mRNA expression of BT474 cells treated with different drugs mentioned above were sequenced and uploaded. In the expression matrix we uploaded, A stands for pyrotinib treatment, B stands for tamoxifen treatment, C stands for dalpiciclib treatment, AB stands for pyrotinib+tamoxifen treatment, AC stands for pyrotinib+dalpiciclib treatment, BC stands for tamoxifen+dalpiciclib treatment and ABC stands for pyrotinib+tamoxifen+dalpiciclib treatment. |
| Sample scope |
Monoisolate |
| Release date |
2023-03-13 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 36602226
|
Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer
|
eLife
|
10.7554/eLife.85246
|
2023
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Natural Science Foundation of China (NSFC)
|
General Program
|
U20A20381
|
|
|
|
| Submitter |
Caigang
Liu (liucg@sj-hospital.org)
|
| Organization |
Shengjing Hospital of China Medical University |
| Submission date |
2022-12-04 |
